Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Nov 03, 2014

PTC Therapeutics Expands Access For Translarna™ (Ataluren)

-Italian Medicines Agency (AIFA) approves cohort early access program -

Oct 29, 2014

PTC Therapeutics to Present at the Credit Suisse 23rd Annual Healthcare Conference

SOUTH PLAINFIELD, N.J. , Oct. 29, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Credit Suisse 23 rd Annual Healthcare Conference on Tuesday, November 11 th at 4:30 pm MT at the Arizona Biltmore in Phoenix, Arizona .

Oct 27, 2014

Translarna™ Phase 2b Data Published in Muscle & Nerve

Data Supports Benefit in Nonsense Mutation Duchenne Muscular Dystrophy Patients

Oct 23, 2014

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2014 Financial Results

SOUTH PLAINFIELD, N.J. , Oct. 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2014 financial results and provide an update on the company's business and outlook on Thursday, November 6,

Oct 09, 2014

PTC Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH PLAINFIELD, N.J. , Oct. 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the

Oct 08, 2014

PTC Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH PLAINFIELD, N.J. , Oct. 8, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it is commencing an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed

Sep 24, 2014

PTC Therapeutics to Present at the Leerink Partners Rare Disease Roundtable

SOUTH PLAINFIELD, N.J. , Sept. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1st at 8:25 am ET at Le Parker Meridien in New York City .

Sep 24, 2014

SOUTH PLAINFIELD, N.J. , Sept. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 23, 2014 it approved non-statutory stock options to purchase an aggregate of 208,300 shares of its common stock to eighteen new employees.

Sep 17, 2014

PTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J. , Sept. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its global presence with the addition of key executives to leadership positions in PTC's global commercial team and the establishment of its international headquarters

Sep 09, 2014

PTC THERAPEUTICS COMPLETES ENROLLMENT OF LANDMARK TRIAL IN DUCHENNE MUSCULAR DYSTROPHY

- Top-line data expected H2 2015- -Data intended to support applications for additional approvals globally

Pagination

First page
Previous page
…
Page 43
Page 44
Current page 45
Page 46
Page 47
…
Next page
Last page